Lilly's Retatrutide Posts Up to 28% Weight Loss in First Phase 3 Obesity Readout

Eli Lilly and Company announced on May 21, 2026 that retatrutide, an investigational once-weekly peptide, met the primary and key secondary endpoints of TRIUMPH-1, the first Phase 3 readout from its late-stage obesity program. The randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier NCT05929066) enrolled 2,339 adults with obesity, or overweight with at least one weight-related complication, who did not have type 2 diabetes.

Retatrutide is a triple hormone receptor agonist designed to act on the GIP, GLP-1 and glucagon receptors, distinguishing it mechanistically from single- and dual-receptor drugs already on the market. Under the efficacy estimand, which estimates effects assuming participants stayed on treatment, average weight loss at 80 weeks was 19.0% (about 47.2 pounds) at the 4 mg dose, 25.9% (about 64.4 pounds) at 9 mg and 28.3% (about 70.3 pounds) at 12 mg. Under the more conservative treatment-regimen estimand, which accounts for discontinuation, the 12 mg dose produced an average reduction of 25.0%, compared with placebo.

Lilly reported that the safety profile was consistent with the incretin-based drug class, with gastrointestinal effects the most commonly reported adverse events. Discontinuations attributed to adverse events were 4.1%, 6.9% and 11.3% for the 4 mg, 9 mg and 12 mg doses respectively, versus 4.9% for placebo. In its announcement, the company framed the data as supporting retatrutide's potential across a range of obesity severity.

TRIUMPH-1 is one component of a broad Phase 3 program spanning obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease and cardiovascular outcomes. In December 2025, Lilly reported results from TRIUMPH-4, which studied adults with obesity and knee osteoarthritis; participants on the 12 mg dose lost an average of 28.7% of body weight at 68 weeks. Additional TRIUMPH readouts were expected through 2026.

The figures released in May were topline results disclosed in a corporate announcement and had not yet been peer-reviewed or presented in full at a scientific meeting. Cross-trial comparisons with other obesity medicines are imprecise because trial designs, durations, populations and statistical estimands differ, and the company had not disclosed a specific timeline for regulatory submissions in the announcement.

Retatrutide remains investigational. It has not been approved by the FDA, the European Medicines Agency or any other regulator, and the trial data describe study outcomes rather than any authorized use.